These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies. Bodey B; Siegel SE; Kaiser HE Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112 [TBL] [Abstract][Full Text] [Related]
5. Preparation and use of therapeutic antibodies primarily of human origin. Stiehm ER; Keller MA; Vyas GN Biologicals; 2008 Nov; 36(6):363-74. PubMed ID: 18789721 [TBL] [Abstract][Full Text] [Related]
6. Epratuzumab in the therapy of oncological and immunological diseases. Goldenberg DM Expert Rev Anticancer Ther; 2006 Oct; 6(10):1341-53. PubMed ID: 17069520 [TBL] [Abstract][Full Text] [Related]
7. Adverse effects of the humanized antibodies used as cancer therapeutics. Klastersky J Curr Opin Oncol; 2006 Jul; 18(4):316-20. PubMed ID: 16721123 [TBL] [Abstract][Full Text] [Related]
8. Adhesion molecules as therapeutic targets in the treatment of allergic and immunologically mediated diseases. Kavanaugh A Clin Immunol Immunopathol; 1996 Sep; 80(3 Pt 2):S15-22. PubMed ID: 8811059 [TBL] [Abstract][Full Text] [Related]
10. Immunotherapy in clinical medicine: historical perspective and current status. Shahani L; Singh S; Khardori NM Med Clin North Am; 2012 May; 96(3):421-31, ix. PubMed ID: 22703849 [TBL] [Abstract][Full Text] [Related]
11. Polymorphisms of immunoglobulin receptors and the effects on clinical outcome in cancer immunotherapy and other immune diseases: a general review. Kaifu T; Nakamura A Int Immunol; 2017 Jul; 29(7):319-325. PubMed ID: 28910969 [TBL] [Abstract][Full Text] [Related]
12. Evaluating the validity of animal models for research into therapies for immune-based disorders. 't Hart BA; Amor S; Jonker M Drug Discov Today; 2004 Jun; 9(12):517-24. PubMed ID: 15183159 [TBL] [Abstract][Full Text] [Related]
13. Hazard identification and risk assessment for biologics targeting the immune system. Weir AB J Immunotoxicol; 2008 Jan; 5(1):3-10. PubMed ID: 18382852 [TBL] [Abstract][Full Text] [Related]
14. Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases. Chang TW; Wu PC; Hsu CL; Hung AF Adv Immunol; 2007; 93():63-119. PubMed ID: 17383539 [TBL] [Abstract][Full Text] [Related]
15. The use of antibodies in the treatment of infectious diseases. Chan CE; Chan AH; Hanson BJ; Ooi EE Singapore Med J; 2009 Jul; 50(7):663-72; quiz 673. PubMed ID: 19644620 [TBL] [Abstract][Full Text] [Related]
16. The Case for Adjunctive Monoclonal Antibody Immunotherapy in Schizophrenia. Miller BJ; Buckley PF Psychiatr Clin North Am; 2016 Jun; 39(2):187-98. PubMed ID: 27216899 [TBL] [Abstract][Full Text] [Related]
17. [Infusion reactions]. Sato K; Kohgo Y Gan To Kagaku Ryoho; 2008 Oct; 35(10):1671-4. PubMed ID: 18931569 [TBL] [Abstract][Full Text] [Related]
18. The expanding role of therapeutic antibodies. Salemi S; Markovic M; Martini G; D'Amelio R Int Rev Immunol; 2015 May; 34(3):202-64. PubMed ID: 24471447 [TBL] [Abstract][Full Text] [Related]
19. [Role of monoclonal antibodies in the treatment of immune-mediated kidney disease: an introduction]. Feriozzi S G Ital Nefrol; 2012; 29(3):267-73; discussion 292. PubMed ID: 22718449 [TBL] [Abstract][Full Text] [Related]
20. Biological Therapies of Immunologic Diseases: Strategies for Immunologic Interventions. Polk BI; Rosenwasser LJ Immunol Allergy Clin North Am; 2017 May; 37(2):247-259. PubMed ID: 28366475 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]